MA53689A1 - Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application - Google Patents

Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application

Info

Publication number
MA53689A1
MA53689A1 MA53689A MA53689A MA53689A1 MA 53689 A1 MA53689 A1 MA 53689A1 MA 53689 A MA53689 A MA 53689A MA 53689 A MA53689 A MA 53689A MA 53689 A1 MA53689 A1 MA 53689A1
Authority
MA
Morocco
Prior art keywords
antibody
receptor family
methods
application
antibodies against
Prior art date
Application number
MA53689A
Other languages
English (en)
Other versions
MA53689B1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Roman Alekseevich Ivanov
Pavel Andreevich Iakovlev
Anna Konstantinovna Vladimirova
Dmitry Valentinovich Morozov
?Lga Vladimirovna Britanova
Arina Vitalevna Anikina
Mariia Aleksandrovna Shchemeleva
Alexey Konstantinovich Misorin
Dmitry Borisovich Staroverov
Anna Valentinovna Evstrateva
Sergey Anatolievichvna Lukyanov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA53689A1 publication Critical patent/MA53689A1/fr
Publication of MA53689B1 publication Critical patent/MA53689B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un anticorps monoclonal humanisé ou son fragment de liaison d'antigène qui se lient spécifiquement à la famille trbv-9 des récepteurs cellulaires t de l'humain. L'invention concerne également un acide nucléique codant pour cet anticorps ou un fragment de liaison à un antigène de celui-ci, un vecteur d'expression, un procédé de production d'un anticorps et l'utilisation d'un anticorps pour traiter des maladies ou des troubles associés à la famille des récepteurs des lymphocytes t humains. L'invention vise notamment la création d'anticorps qui peuvent être utilisés pour la thérapie, notamment lors d'une spondylarthrite ankylosante (sa ou maladie de bechterew), de la la maladie cœliaque et des maladies sanguines malignes dont la pathogenèse est liée à l'implication du récepteur des cellules t trbv9.
MA53689A 2018-12-25 2020-02-20 Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application MA53689B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
PCT/RU2020/050024 WO2020139175A2 (fr) 2018-12-25 2020-02-20 Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application

Publications (2)

Publication Number Publication Date
MA53689A1 true MA53689A1 (fr) 2022-06-30
MA53689B1 MA53689B1 (fr) 2023-03-31

Family

ID=69184123

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53689A MA53689B1 (fr) 2018-12-25 2020-02-20 Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application

Country Status (25)

Country Link
US (1) US20220112286A1 (fr)
EP (1) EP3907239A4 (fr)
JP (1) JP2022532274A (fr)
KR (2) KR20210119404A (fr)
CN (2) CN113646333A (fr)
AR (1) AR117734A1 (fr)
AU (1) AU2020204492A1 (fr)
BR (1) BR112021012555A2 (fr)
CA (2) CA3127767A1 (fr)
CL (1) CL2021001705A1 (fr)
CO (2) CO2021008218A2 (fr)
CR (1) CR20210354A (fr)
EA (1) EA202191813A1 (fr)
EC (1) ECSP21046333A (fr)
IL (1) IL284370A (fr)
JO (1) JOP20210169A1 (fr)
MA (1) MA53689B1 (fr)
MX (1) MX2021007719A (fr)
PE (1) PE20220217A1 (fr)
PH (1) PH12021551532A1 (fr)
RU (1) RU2712251C1 (fr)
SG (1) SG11202106975VA (fr)
TW (1) TW202039574A (fr)
WO (2) WO2020091635A2 (fr)
ZA (1) ZA202104357B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
WO2010151416A1 (fr) * 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Procédé de mesure de l'immunité adaptative
EP3202784A1 (fr) * 2016-02-08 2017-08-09 Polybiocept AB Séquences de récepteurs de lymphocytes t pour une immunothérapie active
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Also Published As

Publication number Publication date
SG11202106975VA (en) 2021-07-29
RU2712251C1 (ru) 2020-01-27
ECSP21046333A (es) 2021-07-30
WO2020139175A3 (fr) 2020-10-29
MX2021007719A (es) 2022-03-25
WO2020139175A2 (fr) 2020-07-02
MA53689B1 (fr) 2023-03-31
JOP20210169A1 (ar) 2023-01-30
KR20220131489A (ko) 2022-09-28
CO2021009689A2 (es) 2021-08-09
WO2020091635A2 (fr) 2020-05-07
US20220112286A1 (en) 2022-04-14
KR20210119404A (ko) 2021-10-05
PE20220217A1 (es) 2022-02-02
CA3127767A1 (fr) 2020-05-07
IL284370A (en) 2021-08-31
WO2020091635A3 (fr) 2020-10-22
CO2021008218A2 (es) 2021-07-30
EP3907239A2 (fr) 2021-11-10
AU2020204492A1 (en) 2021-08-12
CR20210354A (es) 2021-12-20
JP2022532274A (ja) 2022-07-14
CN113646333A (zh) 2021-11-12
BR112021012555A2 (pt) 2021-09-14
AR117734A1 (es) 2021-08-25
CL2021001705A1 (es) 2022-01-28
EA202191813A1 (ru) 2021-10-07
TW202039574A (zh) 2020-11-01
ZA202104357B (en) 2022-09-28
CA3124813A1 (fr) 2020-07-02
EP3907239A4 (fr) 2022-10-05
PH12021551532A1 (en) 2022-02-28
CN114144432A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
MA50128B1 (fr) Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
CA3095443A1 (fr) Procedes a base d'anticorps de detection et de traitement de la maladie d'alzheimer
BG66209B1 (bg) Методи за получаване на антитела с двойна специфичност
CN106661103A (zh) 改进的Aβ初原纤维结合抗体
MA53689B1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
JP2898040B2 (ja) ｇｐ１３０蛋白質に対する抗体
TW201831520A (zh) 針對抗pd-l1抗體之個體遺傳型抗體及其使用
KR20210143858A (ko) 피로글루타메이트 아밀로이드-β에 대한 항체 및 이의 용도
CN112119091A (zh) 抗序列相似家族19成员a5的抗体及其使用方法
CN111518207B (zh) 人源化抗Aβ单克隆抗体及其应用
CN114578066A (zh) 检测β-淀粉样蛋白的产品和方法
JP2018537081A (ja) Ｄ因子活性及びｄ因子阻害剤の力価を測定する方法
WO2002059154A3 (fr) Utilisation de souris transgenique pour isoler efficacement de nouveaux anticorps monoclonaux humains a activite de neutralisation de souches primaires du vih-1 et nouveaux anticorps de neutralisation du vih-1
CN111518205B (zh) 人源化抗Aβ单克隆抗体及其应用
US20210139568A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
JP7256172B2 (ja) ミニブタ試料において抗薬物抗体を決定するための方法
WO2024012434A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et leur utilisation pharmaceutique
JPH06217790A (ja) 薬物耐性を付与するタンパク質と反応性の抗体およびそれを用いる方法
JP2009139372A (ja) ラットＩｇＥ測定試薬